Last reviewed · How we verify
Ranibizumab plus Photodynamic therapy
Ranibizumab blocks vascular endothelial growth factor (VEGF) to reduce abnormal blood vessel growth, while photodynamic therapy uses light-activated drugs to destroy diseased retinal tissue.
Ranibizumab blocks vascular endothelial growth factor (VEGF) to reduce abnormal blood vessel growth, while photodynamic therapy uses light-activated drugs to destroy diseased retinal tissue. Used for Wet age-related macular degeneration (AMD), Choroidal neovascularization secondary to pathologic myopia.
At a glance
| Generic name | Ranibizumab plus Photodynamic therapy |
|---|---|
| Also known as | Lucentis, Visudyne |
| Sponsor | Illinois Retina Associates |
| Drug class | Anti-VEGF monoclonal antibody fragment combined with photodynamic therapy |
| Target | VEGF-A (ranibizumab component) |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Ranibizumab is a monoclonal antibody fragment that inhibits VEGF-A, preventing neovascularization and vascular leakage in the retina. Photodynamic therapy (PDT) involves intravenous administration of a photosensitizing agent followed by laser activation to selectively destroy abnormal choroidal neovascularization. The combination targets both the angiogenic driver (VEGF) and the pathological vasculature directly.
Approved indications
- Wet age-related macular degeneration (AMD)
- Choroidal neovascularization secondary to pathologic myopia
Common side effects
- Conjunctival hemorrhage
- Eye pain
- Floaters
- Photopsia
- Vision blurred
- Endophthalmitis
Key clinical trials
- Comparative Study With Photodynamic Therapy And Triamcinolone Versus Photodynamic Therapy, Triamcinolone And Ranibizumab In Patients With Subfoveal Choroidal Neovascularization (PHASE2, PHASE3)
- Optical Coherence Tomography Angiography (OCTA) - Directed PDT Triple Therapy (PHASE4)
- Safety Study of 2.0mg Lucentis to Treat Polypoidal Choroidal Vasculopathy (PHASE1, PHASE2)
- Reduced Fluence Photodynamic Therapy (PDT) With Visudyne in Combination With Lucentis for Age-Related Macular Degeneration (PHASE4)
- Visual Outcome in Patients With Symptomatic Macular Polypoidal Choroidal Vasculopathy (PCV) Treated With Either Ranibizumab as Monotherapy or Combined With Verteporfin Photodynamic Therapy (vPDT) (PHASE4)
- Intraocular Cytokines in Non-responders to Ranibizumab Treatment for Neovascular AMD
- Lucentis Utilizing Visudyne (LUV Trial) Combination Therapy in the Treatment of Age-Related Macular Degeneration (PHASE4)
- Triple Treatment for Detachment of Retinal Pigment Epithelium Secondary to Polypoidal Choroidal Vasculopathy (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: